West Pharmaceutical Services, Inc. (NYSE:WST) Receives $355.55 Consensus PT from Analysts

West Pharmaceutical Services, Inc. (NYSE:WST) has earned an average rating of “Buy” from the fifteen ratings firms that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $363.1667.

Several brokerages have recently issued reports on WST. Evercore reaffirmed an “outperform” rating and issued a $410.00 price objective on shares of West Pharmaceutical Services in a research note on Monday, July 6th. Barclays raised shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $310.00 to $400.00 in a research note on Tuesday, June 9th. TD Cowen restated a “buy” rating on shares of West Pharmaceutical Services in a report on Wednesday. Citigroup restated a “buy” rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. Finally, KeyCorp upped their price target on West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a report on Thursday, July 2nd.

Insiders Place Their Bets

In related news, VP Annette F. Favorite sold 2,817 shares of the stock in a transaction on Monday, April 27th. The stock was sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the transaction, the vice president owned 16,828 shares in the company, valued at $5,135,905.60. This trade represents a 14.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Chad Winters sold 896 shares of West Pharmaceutical Services stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $300.67, for a total value of $269,400.32. Following the completion of the transaction, the chief accounting officer directly owned 1,523 shares in the company, valued at $457,920.41. This represents a 37.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.60% of the company’s stock.

Institutional Trading of West Pharmaceutical Services

Hedge funds have recently bought and sold shares of the company. Holocene Advisors LP purchased a new position in West Pharmaceutical Services in the third quarter valued at about $49,085,000. Nordea Investment Management AB raised its stake in shares of West Pharmaceutical Services by 42.7% during the 4th quarter. Nordea Investment Management AB now owns 14,950 shares of the medical instruments supplier’s stock worth $4,122,000 after purchasing an additional 4,477 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of West Pharmaceutical Services by 7.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 236,963 shares of the medical instruments supplier’s stock worth $62,163,000 after purchasing an additional 16,919 shares in the last quarter. Birch Hill Investment Advisors LLC lifted its holdings in shares of West Pharmaceutical Services by 11.5% during the 4th quarter. Birch Hill Investment Advisors LLC now owns 152,148 shares of the medical instruments supplier’s stock valued at $41,862,000 after buying an additional 15,678 shares during the last quarter. Finally, Brendel Financial Advisors LLC acquired a new stake in shares of West Pharmaceutical Services during the 4th quarter valued at about $3,742,000. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Trading Down 1.0%

Shares of West Pharmaceutical Services stock opened at $358.77 on Friday. The business has a fifty day simple moving average of $332.71 and a 200-day simple moving average of $284.80. West Pharmaceutical Services has a fifty-two week low of $206.80 and a fifty-two week high of $367.66. The firm has a market cap of $25.35 billion, a price-to-earnings ratio of 47.96, a price-to-earnings-growth ratio of 2.90 and a beta of 1.16. The company has a quick ratio of 2.04, a current ratio of 2.71 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.68 by $0.45. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The firm had revenue of $844.90 million for the quarter, compared to analyst estimates of $779.67 million. During the same period in the previous year, the company earned $1.45 earnings per share. West Pharmaceutical Services’s revenue was up 21.0% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, equities analysts forecast that West Pharmaceutical Services will post 8.6 EPS for the current fiscal year.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.